

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. **514862000100**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: September 19, 2001

By: Michael R. Ward

Michael R. Ward  
Registration No. (38,651)

Morrison & Foerster LLP  
425 Market Street  
San Francisco, California 94105-2482  
Telephone: (415) 268-6237  
Facsimile: (415) 268-7522

09937110-012902

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Claims:**

15. (New) A method for treating diseases in humans caused by infection by *H. pylori* of human gastric mucosa comprising administering to a human patient in need thereof an effective amount of a fucosylated N-acetyl lactosamine carbohydrate structure.

16. (New) The method according to claim 15 wherein said lactosamine carbohydrate structure is sialyl-Lewis antigen carbohydrate structure.

17. (New) A method according to claim 17 wherein said sialyl-Lewis antigen carbohydrate structure binds to adhesins on the surface of *H. pylori*.

18. (New) A method according to claim 16 wherein the sialyl-Lewis antigen carbohydrate structure substantially reduces the adhesion of *H. pylori* to epithelial cells of a histological section of human gastric mucosa.

19. (New) A method according to claim 16 wherein the sialyl-Lewis antigen is selected from sialyl-Lewis x and sialyl-Lewis a.

20. (New) A method according to claim 17 wherein the sialyl-Lewis antigen is selected from sialyl-Lewis x and sialyl-Lewis a.

21. (New) A method according to claim 18 wherein the sialyl-Lewis antigen is selected from sialyl-Lewis x and sialyl-Lewis a.

22. (New) A method according to claim 16 wherein the sialyl-Lewis antigen is selected from dimeric or repetitive sialyl-Lewis x and dimeric or repetitive sialyl-Lewis a.

23. (New) A method according to claim 17 wherein the sialyl-Lewis antigen is selected from dimeric or repetitive sialyl-Lewis x and dimeric or repetitive sialyl-Lewis a.

24. (New) A method according to claim 18 wherein the sialyl-Lewis antigen is selected from dimeric or repetitive sialyl-Lewis x and dimeric or repetitive sialyl-Lewis a.

25. (New) A method of treating diseases in humans caused by infection by *H. pylori* of human gastric mucosa comprising administering to a patient in need thereof an effective amount of antibodies to a fucosylated sialylated N-acetyl lactosamine carbohydrate structure.

26. (New) A method of claim 25 wherein said lactosamine structure is sialyl-Lewis x carbohydrate structure.